4594
BrightPath Biotherapeutics Co.,Ltd.
ブライトパス・バイオ
- Industry
- Pharmaceutical
- Market
- Growth
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Non-consolidated
Key metrics
Revenue(thousand JPY)
Mar 2022
15,408
Mar 2023
5,280
Mar 2024
72
Mar 2025
1,133
Mar 2026
84
Operating profit(thousand JPY)
Mar 2022
-1,476,033
Mar 2023
-1,467,059
Mar 2024
-1,155,078
Mar 2025
-1,160,918
Mar 2026
-1,295,001
Operating profit margin(%)
Mar 2022
-9,579.65
Mar 2023
-27,785.21
Mar 2024
-1,604,275
Mar 2025
-102,464.08
Mar 2026
-1,541,667.86
Profit before tax(thousand JPY)
Mar 2022
-1,481,772
Mar 2023
-1,483,733
Mar 2024
-1,166,182
Mar 2025
-1,149,249
Mar 2026
-1,302,531
Profit(thousand JPY)
Mar 2022
-1,484,192
Mar 2023
-1,485,633
Mar 2024
-1,168,082
Mar 2025
-1,151,149
Mar 2026
-1,304,951
Total assets(thousand JPY)
Mar 2022
2,771,202
Mar 2023
1,701,444
Mar 2024
1,230,257
Mar 2025
1,120,612
Mar 2026
2,604,864
Cash and cash equivalents(thousand JPY)
Mar 2022
2,305,026
Mar 2023
1,530,969
Mar 2024
1,057,360
Mar 2025
810,470
Mar 2026
2,156,198
Cash flows from operating activities(thousand JPY)
Mar 2022
-1,512,022
Mar 2023
-1,204,401
Mar 2024
-1,156,920
Mar 2025
-1,250,359
Mar 2026
-1,365,851
Cash flows from investing activities(thousand JPY)
Mar 2022
-17,566
Mar 2023
-1,760
Mar 2024
-7,648
Mar 2025
-1,370
Mar 2026
-1,928
Cash flows from financing activities(thousand JPY)
Mar 2022
569,226
Mar 2023
432,104
Mar 2024
690,959
Mar 2025
1,004,840
Mar 2026
2,713,507
Return on equity(-)
Mar 2022
-
Mar 2023
-
Mar 2024
-
Mar 2025
-
Mar 2026
-
Equity ratio(%)
Mar 2022
90.5
Mar 2023
90.9
Mar 2024
77.7
Mar 2025
80.6
Mar 2026
90.1
Earnings per share(JPY per share)
Mar 2022
-28.55
Mar 2023
-24.9
Mar 2024
-18.21
Mar 2025
-14.12
Mar 2026
-11.7
Net assets per share(JPY per share)
Mar 2022
45.4
Mar 2023
24.6
Mar 2024
13.52
Mar 2025
9.98
Mar 2026
16.91
Dividend per share(-)
Mar 2022
-
Mar 2023
-
Mar 2024
-
Mar 2025
-
Mar 2026
-
Payout ratio(-)
Mar 2022
-
Mar 2023
-
Mar 2024
-
Mar 2025
-
Mar 2026
-
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.